Cargando…

Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days

BACKGROUND: Universal pathogen inactivation of platelet concentrates (PCs) using amotosalen/ultraviolet A with 7‐day storage was implemented in Switzerland in 2011. Routine‐use data were analyzed at the University Hospital Basel, Switzerland. STUDY DESIGN: A retrospective two‐cohort study of patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Infanti, Laura, Holbro, Andreas, Passweg, Jakob, Bolliger, Daniel, Tsakiris, Dimitrios A., Merki, Ramona, Plattner, Alexandra, Tappe, David, Irsch, Johannes, Lin, Jin‐Sying, Corash, Laurence, Benjamin, Richard J., Buser, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Transfusion Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900102/ https://www.ncbi.nlm.nih.gov/pubmed/31574181 http://dx.doi.org/10.1111/trf.15511

Ejemplares similares

Pathogen inactivation treatment of triple‐dose apheresis platelets with amotosalen and ultraviolet a light
por: Infanti, Laura, et al.
Publicado: (2022)

Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance
por: Stivala, Simona, et al.
Publicado: (2017)

Antibody profiles in COVID‐19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment
por: Bagri, Anil, et al.
Publicado: (2022)

Amustaline‐glutathione pathogen‐reduced red blood cell concentrates for transfusion‐dependent thalassaemia
por: Aydinok, Yesim, et al.
Publicado: (2019)

A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVA photochemical treatment
por: Knutson, F, et al.
Publicado: (2015)

Protein Concentrations in Stored Pooled Platelet Concentrates Treated with Pathogen Inactivation by Amotosalen Plus Ultraviolet a Illumination
por: Arnason, Niels Arni, et al.
Publicado: (2022)

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light
por: Lanteri, Marion C., et al.
Publicado: (2020)

Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study
por: Khanna, Nina, et al.
Publicado: (2020)

Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen‐reduction technology
por: Girard, Yvette A., et al.
Publicado: (2020)

Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination
por: Kumar, Ankit, et al.
Publicado: (2022)

Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study
por: Junker, Till, et al.
Publicado: (2023)

Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components
por: Snyder, Edward L., et al.
Publicado: (2022)

Cost implications of implementation of pathogen-inactivated platelets
por: McCullough, Jeffrey, et al.
Publicado: (2015)

Metabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells
por: Rabcuka, Julija, et al.
Publicado: (2022)

Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation
por: Drexler, Beatrice, et al.
Publicado: (2020)

Transfusion of pathogen‐reduced platelet components without leukoreduction
por: Sim, Joycelyn, et al.
Publicado: (2019)

Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies
por: Santa Maria, Felicia, et al.
Publicado: (2022)

Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn
por: Kapur, Rick, et al.
Publicado: (2014)

Association between maternal haemoglobin and stillbirth: a cohort study among a multi‐ethnic population in England
por: Nair, Manisha, et al.
Publicado: (2017)

Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen‐reduced platelets
por: Bahar, Burak, et al.
Publicado: (2019)

The effect of extended c, E and K matching in females under 45 years of age on the incidence of transfusion‐induced red blood cell alloimmunisation
por: Oud, Josine A., et al.
Publicado: (2021)

International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn
por: Lieberman, Lani, et al.
Publicado: (2022)

G-CSF Infusion for Stem Cell Mobilization Transiently Increases Serum Cell-Free DNA and Protease Concentrations
por: Stoikou, Maria, et al.
Publicado: (2020)

Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in human plasma
por: Azhar, Esam I., et al.
Publicado: (2020)

Haplotype sequence collection of ABO blood group alleles by long-read sequencing reveals putative A1-diagnostic variants
por: Gueuning, Morgan, et al.
Publicado: (2022)

Profils d’anticorps dans le plasma de convalescent COVID-19 traité pour traitement de réduction des agents pathogènes par Amotosalen/UVA
por: Corash, Laurence, et al.
Publicado: (2021)

Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet A light
por: Hindawi, S.I., et al.
Publicado: (2022)

Evaluation of amotosalen and UVA pathogen‐reduced apheresis platelets after 7‐day storage
por: Cancelas, Jose A., et al.
Publicado: (2022)

Characterization of pathogen‐inactivated COVID‐19 convalescent plasma and responses in transfused patients
por: Weisser, Maja, et al.
Publicado: (2022)

Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment
por: Keil, Shawn D., et al.
Publicado: (2020)

Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
por: Bubinski, Michal, et al.
Publicado: (2021)

Convalescent plasma treatment of critically ill intensive care COVID‐19 patients
por: Lindemann, Monika, et al.
Publicado: (2021)

CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas
por: Baur, Katharina, et al.
Publicado: (2023)

Iron stores in pregnant women with sickle cell disease: a protocol for a systematic review and meta-analysis
por: Aroke, Desmond, et al.
Publicado: (2019)

Clinical practice of transfusion medicine
Publicado: (1996)

Hemoterapia / Alejandro Benjamín Miroli ; prol. de Vicente Federico del Giudice
por: Miroli, Alejandro Benjamín

Individual Variation in Growth Factor Concentrations in Platelet-rich Plasma and Its Influence on Human Mesenchymal Stem Cells
por: Cho, Hee Soon, et al.
Publicado: (2011)

Bacterial contamination of pediatric whole blood transfusions in a Kenyan hospital
por: Hassall, Oliver, et al.
Publicado: (2009)

Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen– and antibody to hepatitis B core antigen–positive donor
por: Blaich, Annette, et al.
Publicado: (2012)

Increased risk of volume overload with plasma compared with four‐factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
por: Refaai, Majed A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_shr4l83jd096vkgub2usjodab1